The effects of hemoglobin glutamer-200 and iNO on pulmonary vascular tone and arterial oxygenation in an experimental acute respiratory distress syndrome

Combating hypoxemia in COVID-19 patients with a natural oxygen carrier, HEMO2Life® (M101)

“…However, more recently in 2018, Voelker and al [64] showed that pulmonary vasoconstriction by hemoglobin glutamer-200 combined with inhaled nitric oxide did not improve arterial oxygenation in ARDS in a rodent model. HEMO 2 Life® has not yet been the subject of a specific preclinical study for this pathology but we can expect superior efficiency, as it did not provoke vasoconstriction as demonstrated in comparison with the HBOC of the first and second generation [15] .…”

Electrically generated nitric oxide from air: a safe and economical treatment for pulmonary hypertension

“…In Uganda et al demonstrated that breathing NO from cylinders for 48 h was safe in a randomized openlabel, phase II, controlled trial of breathing 80 ppm NO in air or air alone in 92 children with cerebral malaria [13]. In blood transfusion, studies have shown that breathing NO (5-80 ppm) prevents pulmonary hypertension induced by infusion of hemoglobin-based oxygen carriers (HBOCs) or red blood cells stored for prolonged time [5,14]. The administration of inhaled NO (20-80 ppm) from cylinders combined with 2 units of HBOC infusion prevented pulmonary and systemic vasoconstriction, improved cardiac output, arterial oxygen content, and lactate clearance in a patient with acute life-threatening anemia [15].…”

Bone marrow mesenchymal stem cells‐derived exosomes ameliorate LPS‐induced acute lung injury by miR‐223‐regulated alveolar macrophage M2 polarization

“…Acute lung injury (ALI) is a spectrum of progressive respiratory failure resulting from multiple factors. [ 1,2 ] ALI is characterized by non‐cardiogenic pulmonary edema, low alveolar ventilation/perfusion ratios, abnormal physiological shunting of O 2 , bilateral lung injury, and excessive pulmonary inflammation of alveolar epithelial cells, [ 3,4 ] affecting over 190,000 patients and lead 75,000 deaths annually in the United States. [ 5 ] ALI has a poor prognosis with a 46% mortality rate, which might be associated with multiple organ dysfunction syndromes involving the lungs.…”